Current And Emerging Drugs Have No Advantage Over Enbrel In Inhibiting/Slowing The Progression Of Rheumatoid Arthritis

Decision Resources, one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug’s effect on inhibiting/slowing the progression of structural damage and reducing the signs and symptoms of rheumatoid arthritis during the first year of treatment are the attributes that most influence surveyed rheumatologists’ prescribing decisions in the treatment of the disease.

More: continued here

Filed under: Arthritis on April 8th, 2008